haematology
Blood cancers

Pomalidomide for myeloma: Clinical trial results vs real-world experience

In routine practice pomalidomide achieves similar response rates and progression-free survival in refractory myeloma as that reported in a landmark clinical trial, but overall survival benefits are less impressive, a review of Australian patients has concluded. Dr Ashleigh Scott, from Princess Alexandra Hospital in Brisbane, said the benefits of pomalidomide, a third-generation immunomodulatory derivative of ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic